Farydak Coupon & Prices

Is your Farydak medication too expensive?

Get notified when Farydak medication is added to NiceRx

Get Started Now
Medically reviewed by  Jamie Winn, PharmD

Is NiceRx a Farydak coupon provider?

At NiceRx, we help eligible individuals access patient assistance programs. This means that we are not a Farydak coupon, a Farydak discount card, or a Farydak copay card provider. We do not offer any medication trial offers, or free Farydak samples.

Farydak patient assistance program

Patient assistance programs are typically sponsored by pharmaceutical companies and provide free or discounted medications to individuals with low income who are uninsured or under-insured and meet the eligibility criteria that vary by program. There are currently no known patient assistance programs for this medication.

How much does Farydak cost without insurance?

Farydak costs without insurance will vary depending on how much you buy and the retailer you buy it from. As a guide, Farydak oral capsule 10 mg will typically cost around $14,800 for 6 capsules.

How much does Farydak cost with insurance?

The copay of Farydak will vary in line with the specific terms of your healthcare plan. For further details about what you may need to pay, your insurance provider or pharmacist will be able to calculate the copay costs with your current insurance.

What is Farydak?

Farydak is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Secura Bio, Inc. Farydak, is classed as a histone deacetylase inhibitor (HDAC). It is used in combination with bortezomib and dexamethasone, to treat multiple myeloma patients who have received at least 2 prior treatments, including bortezomib and an immunomodulatory agent.

Multiple myeloma is a type of blood cancer that begins in white blood cells called plasma cells. Multiple myeloma causes plasma cells to multiply rapidly, crowding out other blood cells from the bone marrow. Farydak helps to slow the over-development of the plasma cells.

This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be based upon verification and description of clinical benefit in confirmatory trials.

What doses of Farydak are available?

Farydak is available in capsule form, in the following doses: 10 mg, 15 mg, and 20 mg.

20 mg is taken orally once every other day for 3 doses per week (on Days 1, 3, 5, 8, 10, and 12) of Weeks 1 and 2 of each 21-day cycle for 8 cycles. Consider continuing treatment for another 8 cycles for patients with clinical benefit, unless they have unresolved severe or medically significant toxicity.

Please see the full prescribing information for the complete boxed warning and always speak with a healthcare professional about any changes to your dose so they can monitor and evaluate your condition.

Farydak active ingredients

Farydak contains panobinostat as the active ingredient.

Farydak side effects

The most common side effects of Farydak in clinical trials compared to placebo (incidence of at least 20%) include:

  • Diarrhea, decreased appetite, vomiting
  • Tiredness
  • Nausea
  • Peripheral edema
  • Pyrexia
  • Non-hematologic laboratory abnormalities – hypophosphatemia, hypokalemia, hyponatremia, and increased creatinine
  • Hematologic laboratory abnormalities – thrombocytopenia, lymphopenia, leukopenia, neutropenia, and anemia (low red blood cells)

In rare instances, Farydak can cause more serious side effects. These can include:

  • Severe diarrhea
  • Severe and fatal cardiac ischemic events, severe arrhythmias, and QT prolongation. Arrhythmias may be worsened by electrolyte abnormalities. Obtain ECG and electrolytes at baseline and periodically during treatment
  • Fatal and serious cases of gastrointestinal and pulmonary hemorrhage – monitor platelet counts and transfuse as needed
  • Hepatotoxicity – monitor hepatic enzymes and adjust the dosage if necessary
  • Embryo-fetal toxicity

Your doctor will assess the benefits of using Farydak against your risk of adverse events. Patients are encouraged to report negative side effects or adverse reactions of Farydak to the FDA. Visit, or call 1-800-FDA-1088.

Farydak drug interactions

Farydak can interact with other medications. These include:

  • Strong CYP3A4 inhibitors
  • Strong CYP3A4 inducers
  • Sensitive CYP2D6 substrates
  • Anti-arrhythmic drugs
  • QT-prolonging drugs
  • Avoid eating star fruit, pomegranate or pomegranate juice, and grapefruit or grapefruit juice

This list is not exhaustive and other prescription drugs may interact with Farydak.

Farydak contraindications

You should not use Farydak if you:

  • Are allergic to the active ingredient panobinostat
  • Are allergic to any of the other ingredients in Farydak
  • Are pregnant or are planning to become pregnant – Women may need to have a negative pregnancy test before starting treatment. Use effective birth control while you are using this medicine and for at least 3 months after your last dose of Farydak. Men should use effective birth control if their sex partner is able to get pregnant and keep using birth control for at least 6 months after the last dose

Talk to your doctor before using Farydak if you:

  • Are taking any of the medications that could interact with Farydak
  • Have hepatic Impairment
  • Have heart problems, such as long QT syndrome
  • Have any type of infection
  • Have bleeding problems
  • Are breastfeeding or are planning to breastfeed

Farydak generic

Farydak is the trademark brand name for panobinostat manufactured by Secura Bio, Inc. A generic version of panobinostat is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Farydak savings through NiceRx.

Related medications

The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.